New prospective for non-invasive detection, grading, size evaluation, and tumor location of prostate cancer

Prostate

Volumn 70, Issue 15, 2010, Pages 1701-1708

  Cortesi, M ^a   Fridman, E ^b   Volkov, A ^b   Shilstein, Sh ^a   Chechik, R ^a   Breskin, A ^a   Vartsky, D ^c   Raviv, G ^b   Ramon, J ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c NDT   (Israel)

Author keywords

Local therapy control; Patient selection for biopsy; PCa detection; Prostate cancer; Prostatic zinc concentration

Indexed keywords

ZINC;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; COMPUTER SIMULATION; GLEASON SCORE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE PROCESSING; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; TUMOR VOLUME; ADENOCARCINOMA; CANCER STAGING; CHEMISTRY; CYTOCHEMISTRY; LONGITUDINAL STUDY; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; COMPUTER SIMULATION; HISTOCYTOCHEMISTRY; HUMANS; LONGITUDINAL STUDIES; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; ZINC;

EID: 77958190728     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21205     Document Type: Article

References (35)

1. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310 -1319.
2. Schruder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Mttanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320 -1328.
3. Lee TH, Kantoff PW, McNaughton-Collins MF,. Screening for prostate cancer. N Engl J Med 2009; 360: e18.
4. Fall K, Garmo H, Andrén O, Bill-Axelson A, Adolfsson J, Adami HO, Johansson JE, Holmberg L,. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99: 526 -532.
5. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf J-B, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI,. Validation of the contemporary Epstein criteria for insifnificant prostate cancer in European men. Eur Urol 2008; 54: 1306 -1313.
6. Habib FK, Mason MK, Smith PH, Stitch SR,. Cancer of the prostate: Early diagnosis by Zinc and hormone analysis. Br J Cancer 1979; 39: 700 -704.
7. Costello LC, Franklin RB,. The novel role of Zinc in the regulation of citrate metabolism and its implications in prostate cancer. Prostate 1988; 35: 285 -296.
8. Costello LC, Feng P, Milon B, Tan M, Franklin RB,. Role of zinc in the pathogenesis and treatment of prostate cancer: Critical issues to resolve. Pros Cancer Prost Dis 2004; 7: 111 -117 (and references therein).
9. Costello LC, Franklin RB, Liu Y, Kennedy MC,. Zinc causes a shift toward citrate at equilibrium of the m-aconitase reaction of the prostate mitochondria. J Inorg Biochem 2000; 78: 161 -165.
10. Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P,. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999; 40: 200 -207.
11. Iguchi K, Hamatake M, Ishida R,. Induction of necrosis by zinc in prostate carcinoma cells and identification of proteins increased in association with this induction. Eur J Biochem 1998; 253: 766 -770.
12. Zaichick VY, Sviridova TV, Zaichick SV,. Zinc in the human prostate gland: Normal, hyperplastic and cancerous. Int Urol Nephrol 1997; 29: 687 -694 (and references therein).
13. Vartsky D, Shilstein S, Bercovich A, Huszar M, Breskin A, Chechik R, Korotinsky S, Malnick SD, Moriel E,. Prostatic zinc and PSA: An experimental evaluation of their combined diagnostic value. J Urol 2003; 170: 2258 -2262.
14. Shilstein SSh, Cortesi M, Breskin A, Chechik R, Vartsky D, Raviv G, Kleinman N, Ramon J, Kogan G, Gladysh V, Moriel E, Huszar M, Volkov A, Fridman E,. Prostatic Zn determination for prostate cancer diagnosis. Talanta 2006; 70: 914 -921.
15. Cortesi M, Fridman E, Volkov A, Shilstein SSh, Chechik R, Breskin A, Vartsky D, Kleinman N, Kogan G, Moriel E, Gladysh V, Huszar M, Ramon J, Raviv G,. Clinical assessment of the cancer diagnostic value of prostatic zinc: A comprehensive needle-biopsy study. Prostate 2008; 68: 994 -1006.
16. Cortesi M, Chechik R, Breskin A, Vartsky D, Ramon J, Raviv G, Volkov A, Fridman E,. Evaluating the cancer detection and grading potential of prostatic-zinc imaging: A simulation study. Phys Med Biol 2009; 54: 781 -796.
17. Shilstein SS, Breskin A, Chechik R, Feldman G, Vartsky D,. In-vivo determination of prostatic zinc: Phantom feasibility study. J Phys Med Biol 2004; 49: 1 -15.
18. Ramos V, Muge F,. Map segmentation by colour cube genetic K-mean clustering. Lect Notes Comput Sci 2000; 1923: 319 -323.
19. Hand DJ, Till RJ,. A simple generalization of the area under the ROC curve to multiple classification problems. Mach Learn 2001; 45: 171 -186.
20. Boes DC, Graybill FA, Mood AM,. Introduction to the theory of statistics. 3rd edition. New York: McGraw-Hill; 1974.
21. Aslan G, Irer B, Kefi A, Celebi I, Yaraoau K, Esen A,. The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer. Int Urol Nephrol 2005; 37: 511 -514.
22. Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K,. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4 ng/mL. Cancer 2005; 104: 993 -1003.
23. Miyake H, Hara S, Nomi M, Arakawa S, Kamidono S, Hara I,. Value of prostate specific antigen α1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: Comparison with PSA-related parameters. Int J Urol 2002; 8: 589 -593.
24. Chan TY, Partin AW, Walsh PC, Epstein JI,. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000; 56: 823 -827.
25. Mol AJM, Geldof AA, Meijer GA, van der Poel HG, van Moorselaar RJ,. New experimental markers for early detection of high-risk prostate cancer: Role of cell-cell adhesion and cell migration. J Cancer Res Clin Oncol 2007; 133: 687 -695.
26. Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH,. EPCA-2: A highly specific serum marker for prostate cancer. Urology 2007; 69: 714 -720.
27. Jiang Z, et al. Alpha-methylacyl-CoA racemase: A multi-institutional study of a new prostate cancer marker. Histopathology 2004; 45: 218 -225.
28. Marks LS, Bostwick DG,. Prostate cancer specificity of PCA3 gene testing: Examples from clinical practice. Rev Urol 2008; 10: 175 -181.
29. Nakanouchi T, Okihara K, Kojima M, Kojima M, Ukimura O, Yokoyama K, Takamatsu T, Miki T,. Possible use of transrectal power Doppler imaging as an indicator of microvascular density of prostate cancer. Urology 2001; 58: 573 -577.
30. Kravchick S, Cytron S, Peled R, Ben-Dor D, Kravchenko Y,. Colour Doppler ultrasonography for detecting perineural invasion (PNI) and the value of PNI in predicting final pathological stage: A prospective study of men with clinically localized prostate cancer. BJU Int 2003; 92: 28 -31.
31. Moskalik A,. Analysis of three-dimensional ultrasound Doppler for the detection of prostate cancer. Urology 2001; 57: 1128 -1132.
32. Nakashima J, Tanimoto A, Imai Y, Mukai M, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Marumo K, Murai M,. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004; 64: 101 -105.
33. International (PCT) patent application. Method and system for detecting and grading prostate cancer. World Intellectual Property Organization (WIPO), July 2009, number WO 2009/083988.
34. Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG,. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol 1998; 33: 261 -270.
35. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim M,. Focal therapy for localized prostate cancer: A critical appraisal of rational and modalities. J Urol 2007; 178: 2260 -2267.